Live Quote · NASDAQCEREHealthcare· Biotechnology

Cerevel Therapeutics Holdings, Inc.

$44.96 0.74%(+$0.33)
TickerSpark Score
54/100
Mixed
53
Valuation
20
Profitability
15
Growth
80
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CERE research report →

52-Week Range100% of range
Low
$19.59
Current
$44.96
High
$44.99
Company Overviewwww.cerevel.com

About the company

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation.

CEO
Ronald C. Renaud Jr.,
IPO
2020
Employees
355
HQ
Cambridge, MA, US

Price Chart

+70.76% · this period
$44.96$32.61$20.26Aug 02Feb 01Aug 01
Valuation
Market Cap
$8.19B
P/E
-16.83
P/S
0.00
P/B
10.81
EV/EBITDA
-18.46
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-72.44%
ROIC
-38.74%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-432,842,000 · -23.14%
EPS
$-2.67 · -15.09%
Op Income
$-447,265,000
FCF YoY
-16.48%
Performance & Tape
52W High
$44.99
52W Low
$19.59
50D MA
$41.60
200D MA
$38.67
Beta
1.41
Avg Volume
2.06M

Get TickerSpark's AI analysis on CERE

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Aug 1, 24PFIZER INCother27,349,211
Aug 1, 24BAIN CAPITAL INVESTORS LLCsell65,679,781
Aug 1, 24Gordon Christopher Rsell3,282
Aug 1, 24Gordon Christopher Rsell80,189
Aug 1, 24Gordon Christopher Rsell65,679,781
Aug 1, 24Gordon Christopher Rsell10,461
Aug 1, 24Koppel Adamsell3,282
Aug 1, 24Koppel Adamsell65,679,781
Aug 1, 24Koppel Adamsell10,461
Aug 1, 24Koppel Adamsell80,189
Coverage · CERE

Our CERE coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on CERE yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate CERE report →
Internal Compare

Similar companies

Peers in the same neighborhood.